Physician profile
Saad M Juma
NPI 1013931930
$18,600.31
in general payments reported to CMS, 2019-2025
47 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $374 · 2021: $899 · 2022: $843 · 2023: $468 · 2024: $357 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.72 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $13,798.81 | 2019-2025 | Titan |
| Medtronic, INC. | $901.69 | 2021-2025 | Interstim |
| Allergan, INC. | $450.50 | 2019-2022 | |
| Teleflex LLC | $441.62 | 2019-2025 | Barrigel, Urolift |
| Abbvie INC. | $432.11 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $223.88 | 2023-2025 | Gemtesa, Orgovyx |
| Axonics, INC. | $180.00 | 2020-2024 | Axonics |
| Astellas Pharma US INC | $171.48 | 2019-2025 | Veozah |
| Pfizer INC. | $145.43 | 2019-2024 | |
| 180 Medical, INC. | $138.24 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $122.92 | 2019-2025 | Provenge |
| Photocure INC | $117.89 | 2023 | Cysview |
| Urogen Pharma, INC. | $101.57 | 2022-2024 | Jelmyto |
| Myovant Sciences INC. | $100.60 | 2021 | |
| Dentsply Ih INC. | $89.29 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Juma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.